Abstract Essential oils (EO), as new bioactive compounds, have been used for pharmaceutical applications. In this study, EO of Niaouli was found to have a high content in 1,8-cineole (58.53%). Furthermore, pinene, α-terpineol, nerolidol and ledene were found to be its components with an abundance of above 2%. Niaouli EO also had effects as inhibitor of Pseudomonas aeruginosa PAO1 biofilm formation (p<0.05). In the molecular docking study, this effect was explored. The natural ligand OdDHL, the bound ligand TP-1 (Triphenyl-1), the major component 1,8-cineole and the other components with significant abundance were docked against the binding region of the LasR protein. The docking study exhibited that 1,8-cineole together with the other components investigated could inhibit LasR competitively. Its effect on cell viability was also analyzed by MTT assay. Although dose-dependent cell viability effect was observed for all hours (p<0.05), IC50 value was above 100 μg/mL. Therefore, Niaouli can be assessed safely for dermatological applications because of its low toxicity on fibroblast cells and may be considered as potential quorum sensing inhibitor because of its inhibition effect on biofilm formation.

OBJECTIVE: In this study, the relationship between osteoporotic vertebral fractures and 9041 Guanine/Adenine and 3673 Guanine/Adenine polymorphisms related to the vitamin K epoxide reductase complex subunit-1 (VKORC1) gene in postmenopausal women with osteoporosis was investigated. METHOD: DNA was isolated from blood samples collected from 150 women with postmenopausal osteoporosis. Genotyping of the two polymorphic regions (9041 Guanine/Adenine and 3673 Guanine/Adenine) in VKORC1 was performed using polymerase chain reaction–restriction fragment length polymorphism analysis. The presence of radiographic fractures among the 150 patients was ascertained by using the Genant method. RESULT: At least one fracture was detected in 98 patients, and no fracture was observed in 52 patients on radiological images. We found no association between the 9041 Guanine/Adenine (p=0.283) and 3673 Guanine/Adenine (p=0.232) polymorphisms of the VKORC1 gene and the development of secondary postosteoporotic fractures in our study. CONCLUSION: There was no relationship between osteoporotic vertebral fracture and VKORC1 gene polymorphism in a postmenopausal Turkish population.

OBJECTIVE: The development of osteoporosis is associated with several risk factors, such as genetic structures that affect bone turnover and bone mass. The impact of genetic structures on osteoporosis is not known. Plasminogen activator inhibitor type-1 regulates the bone matrix and bone balance. This study assessed the correlation between plasminogen activator inhibitor type-1 gene 4G/5G polymorphisms and osteoporosis in a population of Turkish women. METHODS: A total of 195 postmenopausal female patients who were diagnosed with osteoporosis (Group I) based on bone mineral density measurements via dual-energy x-ray absorptiometry and 90 females with no osteoporosis (Group II) were included in this study. Correlations between PAI-1 gene 4G/5G polymorphisms and osteoporosis were investigated through the identification of PAI-1 gene 4G/5G polymorphism genotypes using the polymerase chain reaction. RESULTS: No significant differences in the genotype and allele frequency of 4G/5G plasminogen activator inhibitor type-1 polymorphisms were observed between the two groups, and both groups exhibited the most frequently observed 4G5G genotype. CONCLUSION: No correlation between the development of osteoporosis in the female Turkish population and 4G/5G plasminogen activator inhibitor type-1 gene polymorphisms was observed.